Table 1 Main features of the 339 reported patients
Total patients (%) | CF Patients (%) | HS Patients (%) | P Value | |
|---|---|---|---|---|
No. | 339 | 141 (41.59) | 198 (58.41) | |
Mean age (range) | 60 (22–86) | 52 (22–79) | 62.5 (38–86) | <0.001 |
Histology | NS | |||
ILC | 30 (8.8) | 12 (8.5) | 18 (9.1) | |
IDC | 299 (88.2) | 126 (89.4) | 173 (87.4) | |
Intraductal | 10 (3) | 3 (21) | 7 (3.5) | |
T stage | NS | |||
T1 | 293 (86.4) | 121 (85.8) | 172 (86.7) | |
T2 | 46 (13.6) | 20 (14.2) | 26 (13.3) | |
N stage | NS | |||
Nx | 21 (6,3) | 8 (5,7) | 13 (6,5) | |
N0 | 251 (74) | 93 (65.9) | 158 (79.8) | |
N1 | 67 (19.7) | 32 (22.6) | 35 (17.6) | |
Grading (Bloom Richardson’s scale) | NS | |||
G1 | 60 (17.7) | 22 (15.6) | 38 (19.2) | |
G2 | 131 (38.6) | 58 (41.1) | 73 (36.8) | |
G3 | 79 (23.3) | 36 (25.5) | 43 (21.7) | |
NA | 69 (20.4) | 25 (17.8) | 44 (22.3) | |
Surgical margins | NS | |||
Negative | 295 (87) | 124 (87.9) | 171 (86.4) | |
Positive | 5 (1.5) | 2 (1.4) | 3 (1.5) | |
Close (< 2 mm) | 27 (8) | 10 (7.1) | 17 (8.6) | |
Tangents | 12 (3.5) | 5 (3.6) | 7 (3.5) | |
Breast Volume | ||||
Average cc | 718.7 | 684 | 725.4 | NS |
(range) | (188.6-2036.7) | (188.6-1899.9) | (193.3-2036.7) | |
Chemotherapy | ||||
Yes | 126 (37.2) | 68 (48.2%) | 58 (29.3%) | |
No | 211 (62.2%) | 72 (51.1%) | 139 (70.2%) | 0.008 |
NA | 2 (0.6%) | 1 (0.7%) | 1 (0.5%) | |
Hormone therapy | ||||
Yes | 247 (72.8) | 101 (71.6) | 146 (73.7) | NS |
No | 74 (21.8) | 34 (24.1) | 40 (20,2) | |
NA | 18 (5.4) | 6 (4.3) | 12 (6.1) | |
Trastuzumab | ||||
Yes | 17 (5) | 7 (5) | 10 (5) | NS |
No | 327 (95) | 134 (95) | 188 (95) |